FDA fast-tracks ADC for non-small cell lung cancer
The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for… Read More